We've found
184,457
clinical trials
We've found
184,457
clinical trials
Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Cancer Associated Thrombosis and Isoquercetin (CAT IQ)
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Cancer Associated Thrombosis and Isoquercetin (CAT IQ)
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials

Cardiology / Vascular Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Cancer Associated Thrombosis and Isoquercetin (CAT IQ)
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 12/31/1969
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Aortic Stenosis Clinical Trial
Updated: 12/31/1969
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials

Osteoarthritis of the Shoulder Clinical Trial
Updated: 12/31/1969
TITAN™ Reverse Shoulder System
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials

Oncology Clinical Trial
Updated: 11/22/2016
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Enrolling,
Phase
II, III
Updated: 11/22/2016
Click here to add this to my saved trials

Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials

Chronic Obstructive Pulmonary Disease Clinical Trial
Updated: 2/26/2016
Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease
Status: Enrolling,
Phase
I, II
Updated: 2/26/2016
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials

Breast Cancer Clinical Trial
Updated: 12/31/1969
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
